Tag: combination

BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- FloBiotech today announced an agreement with UCLA Health to advance a novel class of therapeutics targeting biologically validated protective pathways in neurodegeneration.

New York, New York, June 08, 2026 (GLOBE NEWSWIRE) -- Ocean Capital Acquisition Corporation, a blank check company incorporated in the British Virgin Islands as an exempted company with limited liability (the “Company”), today announced the pricing of its initial public offering (the “IPO” or this “Offering”) of 10,000,000 units (the “Units”) at an offering price of $10.00 per Unit, with each Unit consisting of one ordinary share, one redeemable warrant, and one right to receive one ordinary share upon the consummation of an initial business combination. Each redeemable warrant entitles the holder thereof to purchase one ordinary share of the Company at a price of $11.50 per share, subject to certain adjustments.

New York, New York, June 08, 2026 (GLOBE NEWSWIRE) -- Snow Rothschild Acquisition Corp. (NASDAQ: ISNRU) (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. Each unit issued in the offering consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust acting as trustee.  The Company’s units are expected to be listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ISNRU” and are expected to begin trading on June 9, 2026. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “ISNR” and “ISNRW,” respectively. The closing of the offering is anticipated to take place on or about June 10, 2026, subject to customary closing conditions.

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

First Quarter Revenue Grows 50% to $52.8 Million; Net Income Increases 66% to $2.1 Million with Adjusted EBITDA Up 71% to $4.9 Million; Cash Position Grows to $24.4 Million